The Peptide Field. Selank: approval and evidence record.

Editorial review: 2026-08-30. Dataset version: 2026-09-11.1.

https://thepeptidefield.com/peptides/selank

Lookup: https://thepeptidefield.com/peptide-evidence-checker?peptide=selank#result

This is a dated editorial summary, not a live FDA check or independent medical review. It does not recommend treatment or verify a product in hand.

Status: No FDA-approved U.S. Selank product was found in the records checked on August 30, 2026

Exact product limits: FDA has separate records for Selank and Selank diacetate, a related chemical form. FDA's compounding page uses the name Selank acetate. These records do not show that a sold or compounded product contains the listed form or matches the product used in a study.

Human outcomes: Limited. Small studies compared Selank with anxiety medicines. They reported symptom changes. The records reviewed did not include a large repeat study against a placebo.

Body effects in people: Limited. A 52-person study measured changes in links between brain areas. It did not measure a treatment benefit, focus, memory, or daily function.

What the evidence shows: One study compared Selank with medazepam in 62 people. A second study compared Selank with phenazepam in 60 people with several anxiety-related conditions. Both reported symptom improvement. Neither cited study summary describes a placebo group, and both summaries gave few details about the methods.

A separate study used brain scans in 52 healthy people who received Selank, Semax, or placebo. It found changes in links between some brain areas. It did not test anxiety treatment, focus, memory, or daily function.

What remains unknown: These small studies do not show that Selank is a proven anxiety treatment. They also do not prove better focus, memory, sleep, mood, or daily function. Most reports came from Russian research groups. The reports gave few details about whether people or researchers knew the assigned treatment. They also gave little information about longer follow-up or uncommon harms. No large, independent repeat study was found among the records reviewed.

No FDA-approved U.S. Selank drug was found. FDA says important human safety information is missing for the Selank acetate form. The reviewed records do not show whether an online or compounded product contains the listed chemical form or matches the product used in a study.

Safety limits: FDA warns of possible immune reactions with some ways of using compounded Selank acetate. Peptide clumps or related impurities could cause the reaction. FDA also says important human safety information is missing for this chemical form. Short studies cannot show uncommon or long-term harms. This guide gives no dosing, spray, injection, buying, sourcing, or treatment advice.

Approval claim: “Selank is FDA-approved in the United States.”
Verdict: Misleading. No FDA-approved U.S. Selank product was found in the records checked. FDA's chemical record names the substance. It does not approve a drug. The request to add Selank acetate to a compounding list was withdrawn. That request was not approval.
Evidence basis: Regulatory or product record. Scope: United States drug-approval and compounding records checked on August 30, 2026.
Claim sources: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm https://precision.fda.gov/uniisearch/srs/unii/TS9JR8EP1G https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

Sources used in the full review (a source is not support for every claim):

U.S. Food and Drug Administration. FDA substance record for Selank, Selanc, and TP-7. 2026. Accessed 2026-08-30. https://precision.fda.gov/uniisearch/srs/unii/TS9JR8EP1G

U.S. Food and Drug Administration. FDA current substance record showing the related Selank diacetate form. 2026. Accessed 2026-08-30. https://precision.fda.gov/ginas/app/ui/substances/TS9JR8EP1G

PubMed · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. Selank compared with medazepam in 62 people. 2008. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/18454096/

PubMed · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. Selank compared with phenazepam in 60 people. 2014. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/25176261/

PubMed · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. Phenazepam alone compared with phenazepam plus Selank in 70 people. 2015. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/26356395/

PubMed · Doklady Biological Sciences. Selank, Semax, and placebo brain-scan study in 52 healthy people. 2020. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/32342318/

U.S. Food and Drug Administration. FDA list of withdrawn compounding requests and safety concerns. 2026. Accessed 2026-08-30. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

U.S. Food and Drug Administration. Drugs@FDA approved-drug search. 2026. Accessed 2026-08-30. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm

Keep the limits, review date, and sources with this record. Check the current source for changes.